GAT358 | CB1 NAM

MedKoo Cat#: 128801 | Name: GAT358

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GAT358 is CB1 NAM

Chemical Structure

GAT358

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 128801

Name: GAT358

CAS#: N/A

Chemical Formula: C25H21ClN4O2

Exact Mass: 444.1353

Molecular Weight: 444.92

Elemental Analysis: C, 67.49; H, 4.76; Cl, 7.97; N, 12.59; O, 7.19

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

GAT358; GAT-358; GAT 358

IUPAC/Chemical Name

3-((4-chlorophenyl)amino)-4-((3-(6-(pyrrolidin-1-yl)pyridin-2-yl)phenyl)amino)cyclobut-3-ene-1,2-dione

InChi Key

UFKDVKLQAKDJLO-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H21ClN4O2/c26-17-9-11-18(12-10-17)27-22-23(25(32)24(22)31)28-19-6-3-5-16(15-19)20-7-4-8-21(29-20)30-13-1-2-14-30/h3-12,15,27-28H,1-2,13-14H2

SMILES Code

ClC1=CC=C(NC2=C(NC3=CC(C4=CC=CC(N5CCCC5)=N4)=CC=C3)C(C2=O)=O)C=C1

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 444.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Iyer V, Rangel-Barajas C, Woodward TJ, Kulkarni A, Cantwell L, Crystal JD, Mackie K, Rebec GV, Thakur GA, Hohmann AG. Negative allosteric modulation of CB₁ cannabinoid receptor signaling suppresses opioid-mediated reward. Pharmacol Res. 2022 Nov;185:106474. doi: 10.1016/j.phrs.2022.106474. Epub 2022 Sep 28. PMID: 36179954; PMCID: PMC9948526. 2: Oliva I, Kazi F, Cantwell LN, Thakur GA, Crystal JD, Hohmann AG. Negative allosteric modulation of CB1 cannabinoid receptor signalling decreases intravenous morphine self-administration and relapse in mice. Addict Biol. 2024 Aug;29(8):e13429. doi: 10.1111/adb.13429. PMID: 39109814; PMCID: PMC11304470. 3: Iyer V, Saberi SA, Pacheco R, Sizemore EF, Stockman S, Kulkarni A, Cantwell L, Thakur GA, Hohmann AG. Negative allosteric modulation of CB₁ cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception. Neuropharmacology. 2024 Oct 1;257:110052. doi: 10.1016/j.neuropharm.2024.110052. Epub 2024 Jun 25. PMID: 38936657; PMCID: PMC11261750. 4: Oliva I, Kazi F, Cantwell LN, Thakur GA, Crystal JD, Hohmann AG. Negative allosteric modulation of CB1 cannabinoid receptor signaling decreases intravenous morphine self-administration and relapse in mice. bioRxiv [Preprint]. 2024 Jan 19:2024.01.16.575900. doi: 10.1101/2024.01.16.575900. Update in: Addict Biol. 2024 Aug;29(8):e13429. doi: 10.1111/adb.13429. PMID: 38293046; PMCID: PMC10827159. 5: Iyer V, Saberi SA, Pacheco R, Sizemore EF, Stockman S, Kulkarni A, Cantwell L, Thakur GA, Hohmann AG. Negative allosteric modulation of cannabinoid CB ₁ receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception. bioRxiv [Preprint]. 2024 Jan 6:2024.01.06.574477. doi: 10.1101/2024.01.06.574477. Update in: Neuropharmacology. 2024 Oct 1;257:110052. doi: 10.1016/j.neuropharm.2024.110052. PMID: 38260598; PMCID: PMC10802405.